Boston Scientific Acknowledges Guidant Board's Decision
17 Janvier 2006 - 11:02PM
PR Newswire (US)
NATICK, Mass., Jan. 17 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE:BSX) today issued the following statement in
response to the announcement that Guidant Corporation's (NYSE:GDT)
Board of Directors has determined that Boston Scientific's
definitive offer is superior to Johnson & Johnson's (NYSE:JNJ)
agreement. "We are pleased with Guidant's response, and we look
forward to working together to complete the transaction." Boston
Scientific Corporation Boston Scientific is a worldwide developer,
manufacturer and marketer of medical devices whose products are
used in a broad range of interventional medical specialties. For
more information, please visit: http://www.bostonscientific.com/.
Forward-Looking Statements This press release contains
"forward-looking statements," including, among other statements,
statements regarding the proposed business combination between
Boston Scientific Corporation and Guidant Corporation, and the
anticipated consequences and benefits of such transaction.
Statements made in the future tense, and words such as
"anticipate", "expect", "project", "believe", "plan", "estimate",
"intend", "will", "may" and similar expressions are intended to
identify forward-looking statements. These statements are based on
current expectations, but are subject to certain risks and
uncertainties, many of which are difficult to predict and are
beyond the control of Boston Scientific. Relevant risks and
uncertainties include those referenced in Boston Scientific's
filings with the Securities and Exchange Commission ("SEC") (which
can be obtained as described in "Additional Information" below),
and include: general industry conditions and competition; economic
conditions, such as interest rate and currency exchange rate
fluctuations; technological advances and patents attained by
competitors; challenges inherent in new product development,
including obtaining regulatory approvals; domestic and foreign
health care reforms and governmental laws and regulations; and
trends toward health care cost containment. Risks and uncertainties
relating to the proposed transaction include: Boston Scientific and
Guidant will not enter into any definitive agreement with respect
to the proposed transaction; required regulatory approvals will not
be obtained in a timely manner, if at all; the proposed transaction
will not be consummated; the anticipated benefits of the proposed
transaction will not be realized; and the integration of Guidant's
operations with Boston Scientific will be materially delayed or
will be more costly or difficult than expected. These risks and
uncertainties could cause actual results to differ materially from
those expressed in or implied by the forward-looking statements,
and therefore should be carefully considered. Boston Scientific
assumes no obligation to update any forward-looking statements as a
result of new information or future events or developments.
Additional Information This material is not a substitute for the
prospectus/proxy statement and any other documents Boston
Scientific and Guidant would file with the SEC if a definitive
agreement with Guidant is executed. Investors and security holders
are urged to read such prospectus/proxy statement and any other
such documents, when available, which would contain important
information about the proposed transaction. The prospectus/proxy
statement would be, and other documents filed or to be filed by
Boston Scientific and Guidant with the SEC are or will be,
available free of charge at the SEC's website (http://www.sec.gov/)
or from Boston Scientific by directing a request to Boston
Scientific Corporation, One Boston Scientific Place, Natick,
Massachusetts 01760-1537, Attention: Milan Kofol, Investor
Relations. Boston Scientific is not currently engaged in a
solicitation of proxies from the security holders of Boston
Scientific or Guidant in connection with Boston Scientific's
proposed acquisition of Guidant or in connection with Johnson &
Johnson's proposed acquisition of Guidant. If a proxy solicitation
commences, Boston Scientific, Guidant and their respective
directors, executive officers and other employees may be deemed to
be participants in such solicitation. Information about Boston
Scientific's directors and executive officers is available in
Boston Scientific's proxy statement, dated April 4, 2005, for its
2005 annual meeting of stockholders. Additional information about
the interests of potential participants will be included in the
prospectus/proxy statement Boston Scientific and Guidant would file
if a definitive agreement with Guidant is executed. Contacts Milan
Kofol (508-650-8569) Investor Relations, Boston Scientific
Corporation Paul Donovan (508-650-8541) Media Relations, Boston
Scientific Corporation Steve Frankel / Steve Silva (212-355-4449)
Joele Frank, Wilkinson Brimmer Katcher First Call Analyst: FCMN
Contact: DATASOURCE: Boston Scientific Corporation CONTACT: Milan
Kofol, Investor Relations, +1-508-650-8569, or Paul Donovan, Media
Relations, +1-508-650-8541, both of Boston Scientific Corporation;
or Steve Frankel, or Steve Silva, both of Joele Frank, Wilkinson
Brimmer Katcher, +1-212-355-4449 Web site:
http://www.bostonscientific.com/
Copyright
Guidant (NYSE:GDT)
Graphique Historique de l'Action
De Juil 2024 à Août 2024
Guidant (NYSE:GDT)
Graphique Historique de l'Action
De Août 2023 à Août 2024